scholarly article | Q13442814 |
P819 | ADS bibcode | 2015PLoSO..1019483B |
P356 | DOI | 10.1371/JOURNAL.PONE.0119483 |
P932 | PMC publication ID | 4351071 |
P698 | PubMed publication ID | 25741704 |
P5875 | ResearchGate publication ID | 273148631 |
P50 | author | Raymond J Steptoe | Q59556035 |
Tony J. Kenna | Q37371728 | ||
P2093 | author name string | Hideo Yagita | |
Alan L H Ching | |||
Justin Large | |||
Ryan Galea | |||
Stephen J P Blake | |||
P2860 | cites work | Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells | Q24530100 |
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma | Q24548019 | ||
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice | Q24670319 | ||
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? | Q27002575 | ||
The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. | Q50940546 | ||
Cognate CD4+ help elicited by resting dendritic cells does not impair the induction of peripheral tolerance in CD8+ T cells. | Q53573163 | ||
PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis | Q57083098 | ||
Steady-state dendritic cells expressing cognate antigen terminate memory CD8+ T-cell responses | Q57667259 | ||
CD4+ T Cells Pass Through an Effector Phase During the Process of In Vivo Tolerance Induction | Q61140374 | ||
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis | Q79209903 | ||
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection | Q36737159 | ||
Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade | Q36927966 | ||
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells | Q36986702 | ||
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. | Q37524200 | ||
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application | Q38163290 | ||
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells | Q39122553 | ||
Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity | Q39549328 | ||
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. | Q39763756 | ||
Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. | Q40647086 | ||
A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin | Q42403489 | ||
Targeting antigen to diverse APCs inactivates memory CD8+ T cells without eliciting tissue-destructive effector function | Q44234403 | ||
Transient gain of effector function by CD8+ T cells undergoing peripheral tolerance to high-dose self-antigen | Q44631970 | ||
Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. | Q45377151 | ||
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance | Q47755230 | ||
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions | Q28146072 | ||
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells | Q28243975 | ||
Adoptive immunotherapy for cancer: harnessing the T cell response | Q28262548 | ||
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes | Q28282689 | ||
Restoring function in exhausted CD8 T cells during chronic viral infection | Q28289222 | ||
T cell receptor antagonist peptides induce positive selection | Q29618820 | ||
Immunosuppressive networks in the tumour environment and their therapeutic relevance | Q29619244 | ||
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors | Q29619686 | ||
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma | Q34034408 | ||
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance | Q34122678 | ||
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity | Q34161493 | ||
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. | Q34193534 | ||
Tumor antigen cross-presentation and the dendritic cell: where it all begins? | Q34210664 | ||
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). | Q34484749 | ||
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. | Q34554699 | ||
Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation | Q34570144 | ||
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy | Q34575119 | ||
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells | Q34578170 | ||
A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection | Q34586991 | ||
Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. | Q34589567 | ||
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses | Q34650346 | ||
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. | Q34801069 | ||
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. | Q34827147 | ||
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. | Q34891171 | ||
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo | Q35140721 | ||
The roles of tumor-derived exosomes in cancer pathogenesis | Q35606520 | ||
Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection | Q36024206 | ||
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines | Q36334073 | ||
Migratory properties of naive, effector, and memory CD8(+) T cells | Q36369485 | ||
Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. | Q36376340 | ||
Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells | Q36399420 | ||
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance | Q36544963 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | immunotherapy | Q1427096 |
P304 | page(s) | e0119483 | |
P577 | publication date | 2015-03-05 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment | |
P478 | volume | 10 |
Q47737204 | Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development |
Q40152307 | Antigen presenting cell-targeted proinsulin expression converts insulin-specific CD8+ T-cell priming to tolerance in autoimmune-prone NOD mice |
Q28066199 | Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy |
Q60935183 | Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors |
Q38401589 | Development of novel avenues to overcome challenges facing CAR T cells |
Q37655345 | Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation |
Q92335228 | Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load |
Q27003955 | Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? |
Q99579442 | Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy |
Q36928580 | Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy |
Q46047154 | New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone |
Q98466646 | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors |
Q90049764 | Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions |
Q59349036 | TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade |
Q47252754 | The Role of Tumor Microenvironment in Cancer Immunotherapy. |
Search more.